secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2026-05-19T21:26:35+00:00
Accession:  0001437749-26-017821
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar announces Phase 2 publication: ALXN1840 improves copper balance in Wilson disease
--------------------------------------------------------------------------------

- Cumulative mean decrease in copper balance of -6.08 mg over 21 days (95% CI: -10.18 to -1.98 mg).
- Mean daily change of -0.37 mg (p=0.005) on 15 mg/day dosing; -0.29 mg (p=0.023) overall.
- ~50% increase in fecal copper output-to-intake ratio vs baseline (p=0.041).
- ALXN1840 well tolerated; no serious adverse events reported in the single-arm Phase 2 trial.
- Improvements seen even in patients with mean 16 years prior standard-of-care treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926017821/0001437749-26-017821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926017821/mnpr20260513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-017821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer